Long COVID or post COVID-19 conditions (PCC) occur in a subset of the population infected with SARS-CoV-2 virus that experience persistent symptoms for more than 12 weeks, typically persisting months after recovery from COVID-19 infection and cannot be explained by an alternative diagnosis.
Some of the most common long COVID/PCC symptoms that persist at 6-months include fatigue, anxiety, depression, and impaired attention, concentration, memory and sleep. Patient-Centered Outcomes Research Institute (PCORI) commissioned this emerging technology report for a scoping review of interventions for long COVID/PCC symptoms of fatigue, neurocognition (including brain fog or difficulty thinking or concentrating), chronic anxiety, severe depression, and sleep disorders.
The scoping review will include published and grey literature sources to identify interventions or therapies currently being used in clinical practice, soon to be available, or on the horizon (that is, over the next one to three (1-3) years) for treatment of long COVID/PCC symptoms of interest.
|About the Emerging Technologies and Therapeutics Reports
The Emerging Technologies and Therapeutics Reports provide timely summaries of evidence supporting new drugs, devices, and other healthcare technologies that are recently in use or may be available in the near term in the United States. The documents also identify gaps that need to be addressed for the technologies or therapeutics to move forward.